AstraZeneca’s Tagrisso hits the mark in late-stage lung cancer maintenance study
AstraZeneca’s Tagrisso has improved survival outcomes in a Phase III maintenance test for certain lung cancer patients, paving the way for the drug to expand its market by at least $500 million, according to the company.
The LAURA trial enrolled 216 subjects with unresectable stage 3 epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer whose disease had not progressed after platinum-based chemoradiotherapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.